Paul G. Ambrose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul G. Ambrose has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Sujata M. Bhavnani
11Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany
7 shared publicationsGeorge L. Drusano
11Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany
5 shared publicationsAlan Forrest
SUNY Buffalo, Buffalo, NY 14260, USA
4 shared publicationsEvelyn Ellis-Grosse
3 shared publicationsAlison K. Meagher
2 shared publicationsBrenda B. Cirincione
2 shared publications
Latest Publications
- 1 August 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (S1) , S103-S110
Pharmacokinetic‐Pharmacodynamic Considerations in the Design of Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia Studies: Look before You Leap!
Our thesis is a simple one: although a drug can fail in an individual patient for many reasons, appropriately sized and conducted drug-development programs often fail because of insensitive, uninformative end points, and/or poor a priori regimen decisions. The difficulty in successfully developing antimicrobial agents at present is often exacerbated by company decision-makers who are either uninformed or disregard the difference between empirical-based (ie, akin to playing pin-the-tail on the donkey) and quantitative model-based development plans. Frequently, the focus is on Gantt charts (project event schedules) and the on-time submission of a New Drug Application to a regulatory body, such as the US Food and Drug Administration. Suchmisplaced focus has led and will continue to lead to a number of problems, including program failure or, even worse, regulatory approval of an inappropriate dosing regimen with associated negative safety and efficacy sequelae. We believe that the goal of drug development is not a New Drug Application submitted on time but, rather, an approved, differentiated, safe, and effective new medicine. Here, we focus on the pharmacokinetic-pharmacodynamic data needed to guide dosing regimen decisions for patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia. Early consideration of these data in development programs will reduce risk not only to sponsors but also, most importantly, to the patients enrolled in the clinical trials.
- 1 August 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (S1) , S103-S110
Pharmacokinetic‐Pharmacodynamic Considerations in the Design of Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia Studies: Look before You Leap!
Our thesis is a simple one: although a drug can fail in an individual patient for many reasons, appropriately sized and conducted drug-development programs often fail because of insensitive, uninformative end points, and/or poor a priori regimen decisions. The difficulty in successfully developing antimicrobial agents at present is often exacerbated by company decision-makers who are either uninformed or disregard the difference between empirical-based (ie, akin to playing pin-the-tail on the donkey) and quantitative model-based development plans. Frequently, the focus is on Gantt charts (project event schedules) and the on-time submission of a New Drug Application to a regulatory body, such as the US Food and Drug Administration. Suchmisplaced focus has led and will continue to lead to a number of problems, including program failure or, even worse, regulatory approval of an inappropriate dosing regimen with associated negative safety and efficacy sequelae. We believe that the goal of drug development is not a New Drug Application submitted on time but, rather, an approved, differentiated, safe, and effective new medicine. Here, we focus on the pharmacokinetic-pharmacodynamic data needed to guide dosing regimen decisions for patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia. Early consideration of these data in development programs will reduce risk not only to sponsors but also, most importantly, to the patients enrolled in the clinical trials.
- 1 September 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (9) , 3847-3854
Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection
The pharmacokinetics and pharmacodynamics of a novel liposomal amikacin for inhalation were evaluated in cystic fibrosis patients with chronic pseudomonas infection. Twenty-four patients from two studies received 500 mg of liposomal amikacin by inhalation once daily for 14 days. Serum, sputum, and 24-h urine samples were collected on days 1 and 14 of therapy; pulmonary function tests (PFT) and sputum for quantitative microbiology were assessed at baseline and serially for 14 days. Relationships between amikacin exposure in serum and sputum and absolute change in PFT endpoints and log10CFU ofPseudomonas aeruginosafrom baseline on days 7 and 14 of therapy were assessed. On days 7 and 14, absolute change from baseline in forced expiratory volume in 1 s (FEV1), percent predicted forced expiratory volume in 1 s (FEV1% predicted), and forced expiratory flow between 25 and 75% of forced vital capacity (FEF25-75%) increased by 0.24 (P= 0.002) and 0.13 (P= 0.10) liters, 7.49 (P< 0.001) and 4.38 (P= 0.03), and 0.49 (P< 0.001) and 0.42 (P= 0.02) liters/s, respectively. In addition, relative change from baseline in FEV1% predicted was 10.8% (P< 0.001) and 5.62% (P= 0.073) on days 7 and 14, respectively. While significant relationships between absolute change in PFT endpoints and the ratio of serum or sputum area under the concentration-time curve to the MIC (AUC/MIC) were not observed, relationships between change in log10CFU and serum AUC/MIC ratio and change in log10CFU and absolute changes in all PFT endpoints were significant. Together, these findings likely represent drug effect and warrant the further development of liposomal amikacin for inhalation.
- 1 September 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (9) , 3847-3854
Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection
The pharmacokinetics and pharmacodynamics of a novel liposomal amikacin for inhalation were evaluated in cystic fibrosis patients with chronic pseudomonas infection. Twenty-four patients from two studies received 500 mg of liposomal amikacin by inhalation once daily for 14 days. Serum, sputum, and 24-h urine samples were collected on days 1 and 14 of therapy; pulmonary function tests (PFT) and sputum for quantitative microbiology were assessed at baseline and serially for 14 days. Relationships between amikacin exposure in serum and sputum and absolute change in PFT endpoints and log10CFU ofPseudomonas aeruginosafrom baseline on days 7 and 14 of therapy were assessed. On days 7 and 14, absolute change from baseline in forced expiratory volume in 1 s (FEV1), percent predicted forced expiratory volume in 1 s (FEV1% predicted), and forced expiratory flow between 25 and 75% of forced vital capacity (FEF25-75%) increased by 0.24 (P= 0.002) and 0.13 (P= 0.10) liters, 7.49 (P< 0.001) and 4.38 (P= 0.03), and 0.49 (P< 0.001) and 0.42 (P= 0.02) liters/s, respectively. In addition, relative change from baseline in FEV1% predicted was 10.8% (P< 0.001) and 5.62% (P= 0.073) on days 7 and 14, respectively. While significant relationships between absolute change in PFT endpoints and the ratio of serum or sputum area under the concentration-time curve to the MIC (AUC/MIC) were not observed, relationships between change in log10CFU and serum AUC/MIC ratio and change in log10CFU and absolute changes in all PFT endpoints were significant. Together, these findings likely represent drug effect and warrant the further development of liposomal amikacin for inhalation.
- 1 February 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 63 (2) , 155-159
Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
- 1 February 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 63 (2) , 155-159
Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
- 1 January 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 63 (1) , 38-42
Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints
- 1 January 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 63 (1) , 38-42
Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints
- Open Access
- 1 December 2008
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (S3) , S225-S231
Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community‐Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Regulatory uncertainty has led to the cessation of antimicrobial agent drug development for some community-acquired respiratory tract infections. This uncertainty stems from the fact that many people, including individuals within government, are unsure about the magnitude of drug effect relative to no treatment in patient populations perceived to be at low-to-moderate risk of mortality. Without such information, it is not possible to power noninferiority studies, which, in turn, necessitates the need for superiority study designs. Moreover, many believe that current categorical clinical trial end points (success or failure), determined 7–14 days after therapy, are insensitive measures of drug benefit and that new outcome measures are needed. To date, characterization of the magnitude of treatment effect relative to that of no treatment has not been accomplished through traditional examinations of existing clinical trial databases or evaluations of historical data. However, pharmacokinetic-pharmacodynamic analyses of existing clinical trial data may provide a new context to inform the debate. Herein, we examine pharmacokinetic-pharmacodynamic relationships for efficacy derived from recent clinical drug development programs involving agents for the treatment of community-acquired respiratory tract infections. Through a collective understanding of these data, it may be possible to estimate the no-treatment response rate without exposing patients to any risk incurred by conducting clinical trials with alternative designs (e.g., placebo-controlled studies or studies using suboptimal dose ranges or comparator regimens). Finally, the value and potential of adding continuous, numeric clinical trial end points to those currently used are discussed.
- 1 December 2008
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (S3) , S225-S231
Open AccessUse of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community‐Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Regulatory uncertainty has led to the cessation of antimicrobial agent drug development for some community-acquired respiratory tract infections. This uncertainty stems from the fact that many people, including individuals within government, are unsure about the magnitude of drug effect relative to no treatment in patient populations perceived to be at low-to-moderate risk of mortality. Without such information, it is not possible to power noninferiority studies, which, in turn, necessitates the need for superiority study designs. Moreover, many believe that current categorical clinical trial end points (success or failure), determined 7–14 days after therapy, are insensitive measures of drug benefit and that new outcome measures are needed. To date, characterization of the magnitude of treatment effect relative to that of no treatment has not been accomplished through traditional examinations of existing clinical trial databases or evaluations of historical data. However, pharmacokinetic-pharmacodynamic analyses of existing clinical trial data may provide a new context to inform the debate. Herein, we examine pharmacokinetic-pharmacodynamic relationships for efficacy derived from recent clinical drug development programs involving agents for the treatment of community-acquired respiratory tract infections. Through a collective understanding of these data, it may be possible to estimate the no-treatment response rate without exposing patients to any risk incurred by conducting clinical trials with alternative designs (e.g., placebo-controlled studies or studies using suboptimal dose ranges or comparator regimens). Finally, the value and potential of adding continuous, numeric clinical trial end points to those currently used are discussed.
- 31 May 2008
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 61 (1) , 13-20
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis
- 31 May 2008
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 61 (1) , 13-20
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis
- 1 December 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (12) , 4351-4355
Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model
We determined the pharmacokinetic-pharmacodynamic (PK-PD) measure most predictive of gatifloxacin efficacy and the magnitude of this measure necessary for survival in a murine Bacillus anthracis inhalation infection model. We then used population pharmacokinetic models for gatifloxacin and simulation to identify dosing regimens with high probabilities of attaining exposures likely to be efficacious in adults and children. In this work, 6- to 8-week-old nonneutropenic female BALB/c mice received aerosol challenges of 50 to 75 50% lethal doses of B. anthracis (Ames strain, for which the gatifloxacin MIC is 0.125 mg/liter). Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans. Mice were evaluated daily for survival. Hill-type models were fitted to survival data. To identify potentially effective dosing regimens, adult and pediatric population pharmacokinetic models for gatifloxacin and Monte Carlo simulation were used to generate 5,000 individual patient exposure estimates. The ratio of the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) to the MIC of the drug for the organism (AUC 0-24 /MIC ratio) was the PK-PD measure most predictive of survival ( R 2 = 0.96). The 50% effective dose (ED 50 ) and the ED 90 and ED 99 corresponded to AUC 0-24 /MIC ratios of 11.5, 15.8, and 30, respectively, where the maximum effect was 97% survival. Simulation results indicate that a daily gatifloxacin dose of 400 mg for adults and 10 mg/kg of body weight for children gives a 100% probability of attaining the PK-PD target (ED 99 ). Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter.
- 1 December 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (12) , 4351-4355
Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model
We determined the pharmacokinetic-pharmacodynamic (PK-PD) measure most predictive of gatifloxacin efficacy and the magnitude of this measure necessary for survival in a murine Bacillus anthracis inhalation infection model. We then used population pharmacokinetic models for gatifloxacin and simulation to identify dosing regimens with high probabilities of attaining exposures likely to be efficacious in adults and children. In this work, 6- to 8-week-old nonneutropenic female BALB/c mice received aerosol challenges of 50 to 75 50% lethal doses of B. anthracis (Ames strain, for which the gatifloxacin MIC is 0.125 mg/liter). Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans. Mice were evaluated daily for survival. Hill-type models were fitted to survival data. To identify potentially effective dosing regimens, adult and pediatric population pharmacokinetic models for gatifloxacin and Monte Carlo simulation were used to generate 5,000 individual patient exposure estimates. The ratio of the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) to the MIC of the drug for the organism (AUC 0-24 /MIC ratio) was the PK-PD measure most predictive of survival ( R 2 = 0.96). The 50% effective dose (ED 50 ) and the ED 90 and ED 99 corresponded to AUC 0-24 /MIC ratios of 11.5, 15.8, and 30, respectively, where the maximum effect was 97% survival. Simulation results indicate that a daily gatifloxacin dose of 400 mg for adults and 10 mg/kg of body weight for children gives a 100% probability of attaining the PK-PD target (ED 99 ). Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter.
- 1 November 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11) , 4085-4089
Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation
The objective of these analyses was to assess the penetration of tigecycline into colon wall tissue and epithelial lining fluid (ELF). The analyses included data from subjects without infection (phase 1) and patients with intra-abdominal infections (phase 2/3). Steady-state serum samples were collected from all subjects/patients ( n = 577), while colon wall specimens ( n = 23) and ELF specimens ( n = 30) were obtained from subjects without infection. Tissue and serum data were simultaneously comodeled by using the BigNPAG program, and a four-compartment, open model with zero-order intravenous input and first-order elimination was employed. To examine the full range of tissue penetration and the associated probabilities of occurrence, a 9,999-subject Monte Carlo simulation was performed with two outputs, one for ELF penetration and one for colon wall tissue penetration. Data were well fit using models described above, with all r 2 values above 0.95. For subjects without infection, the median (5th and 95th percentiles) colon wall and ELF penetration ratios were 1.73 (0.160 and 199) and 1.15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution.
- 1 November 2007
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11) , 4085-4089
Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation
The objective of these analyses was to assess the penetration of tigecycline into colon wall tissue and epithelial lining fluid (ELF). The analyses included data from subjects without infection (phase 1) and patients with intra-abdominal infections (phase 2/3). Steady-state serum samples were collected from all subjects/patients ( n = 577), while colon wall specimens ( n = 23) and ELF specimens ( n = 30) were obtained from subjects without infection. Tissue and serum data were simultaneously comodeled by using the BigNPAG program, and a four-compartment, open model with zero-order intravenous input and first-order elimination was employed. To examine the full range of tissue penetration and the associated probabilities of occurrence, a 9,999-subject Monte Carlo simulation was performed with two outputs, one for ELF penetration and one for colon wall tissue penetration. Data were well fit using models described above, with all r 2 values above 0.95. For subjects without infection, the median (5th and 95th percentiles) colon wall and ELF penetration ratios were 1.73 (0.160 and 199) and 1.15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution.
- Top Cited PapersOpen Access
- 1 January 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (1) , 79-86
Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore
Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of ant
- 1 January 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (1) , 79-86
Top Cited PapersOpen AccessAntimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore
Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of ant